2nd Annual Global Summit on HEMATOLOGIC Malignancies

APRIL 18-20, 2019 HILTON TOKYO BAY HOTEL TOKYO, JAPAN

SUMMIT CHAIRS: Kensei Tobinai, MD, PhD John Pagel, MD, PhD Visiting Scientist Chief of Hematologic Malignancies National Cancer Center Swedish Cancer Institute Tokyo, Japan Seattle, Washington, USA 2nd Annual Global Summit on APRIL 18-20, 2019 HEMATOLOGIC HILTON TOKYO BAY HOTEL Malignancies TOKYO, JAPAN

MEETING OVERVIEW

Oncology Meeting Innovation’s (OMI’s) Global Summit on Hematologic Malignancies fosters discussion and debate on the evolution of treatment and features a focused approach towards individual patient populations through case- based discussions. New agents targeting BTK, PI3K delta, and BCL-2, as well as next-generation CD20 monoclonal antibodies, are changing the landscape and treatment paradigms for CLL. Similarly, recent data on drugs targeting CD38, SLAMF7, and HDAC, as well as novel approaches to proteasome inhibition, are advancing the continuum of treatment within multiple myeloma. Furthemore, advances in the understanding of the molecular biology and microenvironment have led to new approaches to treating lymphonma. Compelling data on the effects of novel strategies, such as CAR-T , checkpoint inhibition, and next-generation antibody therapy, have led to an explosion of new information and agents in development for patients with hematologic malignancies. In response to these changes, the summit assembles translational researchers, clinical researchers, and key community oncologists to address the challenges of this rapidly evolving area of . FACULTY

James CS Chim, MD, PhD Seok Jin Kim, MD Keiya Ozawa, MD, PhD S H Ho Professorship in and Professor of Hematology and Oncology Professor of Oncology Samsung Medical Center, Sungkyunkwan Jichi Medical University University of Hong Kong University Shimotsuke, Japan Hong Kong, China Seoul, South Korea John Pagel, MD, PhD CHAIR Steven Coutré, MD Won Seog Kim, MD, PhD Chief of Hematologic Malignancies Professor of Medicine Professor of Hematology and Oncology Swedish Cancer Institute Stanford University Medical Center Samsung Medical Center, Sungkyunkwan Seattle, Washington, USA Stanford, California, USA University Seoul, South Korea Nina Shah, MD Kiyoshi Eshima, MD, PhD Associate Professor Founder and President Zhiming Li, MD, PhD University of California San Francisco Delta-fly Pharma, Inc. Professor San Francisco, California, USA Tokushima, Japan Sun Yat-sen University Cancer Center Gungzhou, China Kazuyuki Shimizu, MD, PhD Hiroshi Handa, MD, PhD Advisor and Supervisor, Department of Director, Department of Hematology Yosuke Minami, MD, PhD Hematology and Oncology Gunma University Graduate School of Medicine Chief, Department of Hematology Higashi Nagoya National Hospital Maebashi, Japan National Cancer Center Hospital East Nagoya, Japan Tokyo, Japan Naoki Hosen, MD, PhD Kensei Tobinai, MD, PhD CHAIR Associate Professor, Department of Cancer Stephen Mulligan, MBBS, PhD Visiting Scientist Stem Cell Biology Adjunct Professor, Senior Staff Specialist and National Cancer Center Hospital Osaka University Graduate School of Medicine Hematologist Tokyo, Japan Osaka, Japan University of Sydney Sydney, Australia Noriko Usui, MD, PhD Jiong Hu Professor, Department of Clinical Oncology Deputy Director, Department of Hematology Wataru Munakata, MD, PhD and Hematology Blood & Marrow Transplantation Center, Staff The Jikei University Daisan Hospital Department of Hematology National Cancer Center Hospital Tokyo, Japan Ruijin Hospital Affiliated to Shanghai Jiao Tong Tokyo, Japan University School of Medicine Jue Wang Shanghai, China Hirokazu Murakami, MD, PhD Tongji Hospital of Huazhong University of Department of Laboratory Science Science and Technology Erlie Jiang, MD, PhD Gunma University Graduate School of Health Wuhan, China Professor Science Institute of Hematology & Blood Diseases Maebashi, Japan Kazuhito Yamamoto, MD, PhD Hospital Chief, Department of Hematology and Cell Tianjin, China Jian Ni, PhD Therapy Chief Executive Officer Aichi Cancer Center Yoshinobu Kanda, MD, PhD Nuance Biotech Co. Ltd. Aichi, Japan Professor of Medicine Suzhou, China Jichi Medical University Xian Zhang, MD Shimotsuke, Japan Michinori Ogura, MD, PhD Chief Physician Director, Department of Hematology and Ludaopei Hospital Oncology Beijing, China Kasugai Municipal Hospital Aichi, Japan 2nd Annual Global Summit on APRIL 18-20, 2019 HEMATOLOGIC HILTON TOKYO BAY HOTEL Malignancies TOKYO, JAPAN

Thursday, April 18, 2019 CLL SETTING THE STAGE Session Chair: Steven Coutré 10:30 AM What is the Role of MRD in CLL Stephen Session Chair: Kensei Tobinai Mulligan 5:00 PM Welcome and Introductions 10:45 AM The Role of Single-agent Steve 5:15 PM Uncovering New Targets for the Nina Shah Ibrutinib in CLL in 2019 and Coutré Treatment of Multiple Myeloma Future Combinations 5:30 PM What is New in FL in 2019? John Pagel 11:00 AM Resistance Mechanisms in CLL Stephen in Novel Rx Era Mulligan 5:45 PM Advances in Salvage Therapy in Wonseog DLBCL in 2019 Kim 11:15 AM Emerging Data on PI3K John Pagel Resistance in CLL 6:00 PM New Immunomodulatory Jian Ni Targets and Next-generation 11:30 AM PANEL DISCUSSION Active Immune Checkpoint 12:00 PM LUNCH Control Immunotherapy 6:15 PM The Development of Novel Wataru BTK Inhibitors for B-cell Munakata INDOLENT AND HODGKIN’S LYMPHOMAS Malignanices Session Chair: Michinori Ogura 6:30 PM Future of FLT3 Treatment in Yosuke 1:00 PM Integrating BTK and Other New Kazuhito AML Minami Targets in MCL Yamamoto 6:45 PM PANEL DISCUSSION 1:15 PM The Treatment of Mantle Cell Yoshinobu 7:45 PM ADJOURN TO WELCOME RECEPTION Lymphoma in Transplant- Kanda eligible Patients 1:30 PM Recent Progress in Treatment of Michinori Friday, April 19, 2019 Newly Diagnosed Advanced FL Ogura 8:00 AM BREAKFAST 1:45 PM PANEL DISCUSSION T-CELL LYMPHOMAS Session Chair: Kensei Tobinai DLBCL 9:00 AM Emerging Role of Gemcitabine- Zhiming Li Session Chair: John Pagel based Combination 2:15 PM Trials to Improve R-CHOP in Michinori for Extranodal Natural Killer/T- DLBCL Ogura cell Lympoma, Nasal Type 2:30 PM Feasibility of CAR-T Therapy for TBD 9:15 AM Targeted Therapy for T-cell Kensei R/R DLBCL Patients in the Real Lymphomas: Recent Progress Tobinai World 9:30 AM How Do We Improve TBD 2:45 PM Can We Finally Start Sub-setting Seok Jin Therapeutic Efficacy for PTCLs? DLBCL in 2019? Kim 9:45 AM PANEL DISCUSSION 3:00 PM PANEL DISCUSSION 10:15 AM BREAK 3:30 PM BREAK 2nd Annual Global Summit on APRIL 18-20, 2019 HEMATOLOGIC HILTON TOKYO BAY HOTEL Malignancies TOKYO, JAPAN

MULTIPLE MYELOMA Saturday, April 20, 2019 Session Chair: Nina Shah 8:00 AM BREAKFAST 3:45 PM Role of Daratumumab in Nina Shah DEBATING TECHNOLOGY: UTILIZING Frontline Multiple Myeloma CURRENT CAR-T THERAPY VS. OPTIMIZING 4:00 PM What’s Next for CAR-T Therapy Naoki FUTURE CARS in MM? Hosen Session Chair: Kensei Tobinai 4:15 PM Development of Fully Human Jue Wang CAR-T Cells Against BCMA for 9:00 AM Finding a Role for Current Keiya R/R Multiple Myeloma CAR-T Technology Ozawa 4:30 PM PANEL DISCUSSION 9:10 AM Necessity of Optimizing CAR-T Nina Shah Technology 4:45 PM The Evolution of M-protein Kazuyuki Measurement Shimizu 9:20 AM PANEL DISCUSSION 5:05 PM Global Genomics in Multiple James Myeloma Chim ACUTE LEUKEMIAS 5:20 PM Non-coding RNA in Multiple Hiroshi Session Chair: Noriko Usui Myeloma Handa 9:50 AM Precision Medicine in AML Yosuke 5:35 PM PANEL DISCUSSION Minami 6:00 PM ADJOURN TO POSTER RECEPTION 10:05 AM Recent Development of AML Noriko Usui Treatment in Asia 10:20 AM Module Technology for Kiyoshi Hematological Cancer Eshima 10:35 AM Next-generation FLT3 Inhibitors Noriko Usui 10:50 AM BREAK 11:10 AM New Approaches to Allogenic Erlie Jiang SCT for MDS and MPN 11:25 AM Advances in Allogenic SCT for Jiong Hu R/R AML 11:40 AM Efficacy and Safety of CD19 Xian Zhang CAR-T Cell Therapy for B-cell Acute Lymphocytic Leukemia 11:55 AM PANEL DISCUSSION 1:00 PM ADJOURN